Kwemeza Minjuvi® (Tafasitamab) hamwe na Lenalidomide mu kuvura abarwayi bakuru bafite Lymphoma ya B-cell B yasubiwemo cyangwa yasubiwemo mu buryo butunguranye mu Bushinwa.

Ku ya 21 Gicurasi 2025, InnoCare Pharma yatangaje ko Ikigo cy’Igihugu cy’Ubushinwa gishinzwe Ibikoresho by’Ubuvuzi (NMPA) cyemeye Minjuvi® (tafasitamab), umuti wa CD19 wahinduwe na Fc wibasira antibody monoclonal, hamwe na lenalidomide, hanyuma Minjuvi ikazanwa na monotherapy, kugira ngo ivurwe abarwayi bakuru bafite lymphoma ya B-cell lymphoma (DLBCL) yasubiwemo cyangwa itarasubirwamo ariko batemerewe gusimbuzwa uturemangingo tw’umubiri (ASCT). Uyu ni wo muti wa mbere wa CD19 wemejwe mu kuvura DLBCL yasubiwemo cyangwa itarasubirwamo mu Bushinwa.

Ku bijyanye na Tafasitamab

Tafasitamab ni ubwoko bwa CD19 yahinduwe na Fc yibanda ku antibody monoclonal. Tafasitamab ikubiyemo urwego rwa Fc rwakozwe mu buryo bwa tekiniki, ruyobora lysis ya B-cell binyuze mu ihinduka ry’uturemangingo tw’umubiri binyuze mu mikorere ya apoptosis no mu buryo bw’imikorere y’ubudahangarwa bw’umubiri harimo Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) na Antibody-Dependent Cellular Phagocytosis (ADCP).

MorphoSys na Incyte bagiranye amasezerano akurikira: (a) muri Mutarama 2020, amasezerano y'ubufatanye n'uburenganzira bwo guteza imbere no gucuruza tafasitamab ku isi yose; na (b) muri Gashyantare 2024, amasezerano aho Incyte yabonye uburenganzira bwihariye bwo guteza imbere no gucuruza tafasitamab ku isi yose.

Muri Kanama 2021, Incyte yagiranye amasezerano y'ubufatanye n'uburenganzira na InnoCare mu guteza imbere no gucuruza tafasitamab mu bijyanye n'amaraso na kanseri mu Bushinwa Bukuru.

Muri Leta Zunze Ubumwe za Amerika, Monjuvi (tafasitamab-cxix) yemejwe byihuse n’Ikigo gishinzwe Ibiribwa n’Imiti muri Amerika hamwe na lenalidomide mu kuvura abarwayi bakuru bafite DLBCL yasubiwemo cyangwa idasubiwemo bitavuzwe ukundi, harimo DLBCL ikomoka kuri lymphoma yo mu rwego rwo hasi, kandi batemerewe guterwa uturemangingo tw’umubiri twitwa autologous (ASCT). Mu Burayi, Minjuvi (tafasitamab) yahawe uburenganzira bwo kwamamaza butangwa n’Ikigo cy’Uburayi gishinzwe imiti hamwe na lenalidomide, hagakurikiraho Minjuvi monotherapy, mu kuvura abarwayi bakuru bafite lymphoma ya B ikomeye yisubiramo cyangwa isubiramo ikwirakwira cyane (DLBCL) itemerewe guterwa uturemangingo tw’umubiri twitwa autologous (ASCT).

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Email：myimmnet@163.com